A recent study indicated that fibroblast activation protein (FAP), which promotes tumor growth and progression, is overexpressed in the CAFs of many human epithelial cancers, including pancreatic cancer, and is an attractive target for marking by 64Cu- and 225Ac-labeled FAP inhibitor FAPI-04, which have been used as theranostics for treating FAP-expressing pancreatic cancer, as shown in a proof-of-concept study [73]. Here, FAP is linked to neoplasm.